Search clinical trials for: Nordihydroguaiaretic Acid

Total 23974 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
University of Iowa
National Cancer Institute (NCI)

Terminated

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Soft Tissue Sarcoma | Recurrent Soft Tissue Sarcoma | Resectable Soft Tissue Sarcoma

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Multiple Myeloma

United States, Puerto Rico
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | Loss of Chromosome 17p

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Margarida Magalhaes-Silverman
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Primary Systemic Amyloidosis | Light Chain Deposition Disease | Extramedullary Plasmacytoma | Isolated Plasmacytoma of Bone

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Rhabdomyosarcoma | Refractory Rhabdomyosarcoma | Recurrent Colon Carcinoma | Recurrent Gastric Carcinoma | Recurrent Rectal Carcinoma | Refractory Sarcoma | Refractory Ovarian Carcinoma | Resectable... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
University Hospital, Tours
University Hospital, Rouen; Central Hospital, Nancy, France; Poitiers University... and other collaborators

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (TRULIGHT)

HIV

France
Stanford University

Terminated

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Lymphoma, Non-Hodgkin | Diffuse Large B-cell Lymphoma (DLBCL) | Lymphoma, B-cell | Malignant Lymphoma, Non-Hodgkin

United States
Children's Oncology Group
National Cancer Institute (NCI); ImmunoGen, Inc.

Withdrawn

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
Fred Hutchinson Cancer Center

Terminated

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Burkitt Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Acute Leukemia in Remission | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Freeman-Sheldon Research Group, Inc.

Withdrawn

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions (FSS-EDICT I)

Craniofacial Abnormalities | Arthrogryposis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | CD20 Positive | Adult Acute Lymphoblastic Leukemia in Complete Remission | Childhood Acute Lymphoblastic Leukemia in Complete Remission | Burkitt Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Sanofi

Recruiting

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

AL Amyloidosis

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Plasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Puerto Rico, Israel
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
QuantumLeap Healthcare Collaborative
M.D. Anderson Cancer Center; University of Colorado, Denver; University of Pennsylvania and other collaborators

Recruiting

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)

COVID-19

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditions

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Plasmacytoma | POEMS Syndrome

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Myeloma | Plasmacytoma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

Search clinical trials for: Nordihydroguaiaretic Acid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations